Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov 8;29(15):1967-1981.
doi: 10.1093/eurjpc/zwac115.

Impact of anthropometric factors on outcomes in atrial fibrillation patients: analysis on 10 220 patients from the European Society of Cardiology (ESC)-European Heart Rhythm Association (EHRA) EurObservational Research Programme on Atrial Fibrillation (EORP-AF) general long-term registry

Giuseppe Boriani  1 , Marco Vitolo  1   2   3 , Vincenzo L Malavasi  1 , Marco Proietti  2   4   5 , Elisa Fantecchi  1 , Igor Diemberger  6 , Laurent Fauchier  7 , Francisco Marin  8 , Michael Nabauer  9 , Tatjana S Potpara  10   11 , Gheorghe-Andrei Dan  12 , Zbigniew Kalarus  13 , Luigi Tavazzi  14 , Aldo Pietro Maggioni  15 , Deirdre A Lane  2   16 , Gregory Y H Lip  2   16 ; ESC-EHRA EORP-AF Long-Term General Registry Investigators
Collaborators, Affiliations
Free article

Impact of anthropometric factors on outcomes in atrial fibrillation patients: analysis on 10 220 patients from the European Society of Cardiology (ESC)-European Heart Rhythm Association (EHRA) EurObservational Research Programme on Atrial Fibrillation (EORP-AF) general long-term registry

Giuseppe Boriani et al. Eur J Prev Cardiol. .
Free article

Abstract

Aim: To investigate the association of anthropometric parameters [height, weight, body mass index (BMI), body surface area (BSA), and lean body mass (LBM)] with outcomes in atrial fibrillation (AF).

Methods and results: Ten-thousand two-hundred twenty patients were enrolled [40.3% females, median age 70 (62-77) years, followed for 728 (interquartile range 653-745) days]. Sex-specific tertiles were considered for the five anthropometric variables. At the end of follow-up, survival free from all-cause death was worse in the lowest tertiles for all the anthropometric variables analyzed. On multivariable Cox regression analysis, an independent association with all-cause death was found for the lowest vs. middle tertile when body weight (hazard ratio [HR] 1.66, 95%CI 1.23-2.23), BMI (HR 1.65, 95%CI 1.23-2.21), and BSA (HR 1.49, 95%CI 1.11-2.01) were analysed in female sex, as well as for body weight in male patients (HR 1.61, 95%CI 1.25-2.07). Conversely, the risk of MACE was lower for the highest tertile (vs. middle tertile) of BSA and LBM in males and for the highest tertile of weight and BSA in female patients. A higher occurrence of haemorrhagic events was found for female patients in the lowest tertile of height [odds ratio (OR) 1.90, 95%CI 1.23-2.94] and LBM (OR 2.13, 95%CI 1.40-3.26).

Conclusions: In AF patients height, weight, BMI, BSA, and LBM were associated with clinical outcomes, with all-cause death being higher for patients presenting lower values of these variables, i.e. in the lowest tertiles of distribution. The anthropometric variables independently associated with other outcomes were also different between male and female subjects.

Keywords: Atrial fibrillation; Body mass index; Lean body mass; Obesity; Outcome; Stroke.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: G.B.: small speaker fee from Medtronic, Boston, Boehringer Ingelheim and Bayer. L.F.: Consultant or speaker for Bayer, BMS/Pfizer, Boehringer Ingelheim, Medtronic, Novartis, and XO. F.M.: Advisor fees Boehringer-Ingelheim, Research Grants Ferrer, Speaker fees Boehringer-Ingelheim, Astra-Zeneca, Pfizer and Bayer; T.P.: Consultant for Bayer and Pfizer (no fees). G.A.D.: Small speaker fees from Boehringer-Ingelheim, Pfizer, Bayer, Sanofi, and Zentiva; L.T. is committee member for Servier and CVIE Therapeutics and speaker for Servier. D.A.L. has received an investigator-initiated educational grant from Bristol-Myers Squibb (BMS); has been a speaker for Boehringer Ingelheim and BMS/Pfizer; and has consulted for BMS, Boehringer Ingelheim, and Daiichi-Sankyo. G.Y.H.L.: Consultant and speaker for Bayer/Janssen, BMS/Pfizer, Boehringer Ingelheim, and Daiichi-Sankyo (No fees are directly received personally). All the disclosures happened outside the submitted work. Other authors have no disclosures to declare.

Comment in

Publication types